Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.54 |
| ▸ | INCENP | Q9NQS7 | 5/20 | 0.54 |
| ▸ | TPX2 | Q9ULW0 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 6/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25941068 | 0.83 | AURKA (0.57) | AURKAAURKBINCENPTPX2MAPT | |
| SCHEMBL20927803 | 0.82 | AURKA (0.56) | AURKAAURKBINCENPTPX2MAPT | |
| SCHEMBL24615534 | 0.82 | AURKA (0.56) | AURKAAURKBINCENPTPX2MAPT | |
| SCHEMBL30559880 | 0.76 | PIM1 (0.51) | AURKAAURKBINCENPTPX2MAPT | |
| Hydrochloric Acid SCHEMBL20919997 | 0.75 | PIM1 (0.50) | AURKAAURKBINCENPTPX2MAPT | |
| SCHEMBL20927905 | 0.74 | KIT (0.53) | AURKAAURKBINCENPTPX2KIT | |
| SCHEMBL1778217 | 0.74 | CCNB2 (0.54) | AURKAAURKBINCENPTPX2 | |
| SCHEMBL24615541 | 0.73 | AURKA (0.48) | AURKAAURKBINCENPTPX2MAPT | |
| SCHEMBL28904590 | 0.72 | KIT (0.48) | AURKAAURKBINCENPTPX2KIT | |
| Hydrochloric Acid SCHEMBL29772761 | 0.72 | AURKA (0.47) | AURKAAURKBINCENPTPX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | AURKA 2056/4885AURKB 1710/4885INCENP 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.